CD274 and non-small cell lung carcinoma: Ricciuiti et al., demonstrated that pathogenic DDR mutations (shown in Figure 2, Panel C) were associated with improved response rate, PFS, and OS in NSCLC patients treated with PD-(L)1 inhibitors as a monotherapy or in combination with a CTLA-4 inhibitor [33].